4 years of revenue, earnings, cash-flow and balance-sheet history from public filings.
Evonile Pharma Limited (NOVARTIND) operates in the Drug Manufacturers - Specialty & Generic industry and is headquartered in Mumbai, India with about 57 employees. Its market capitalization is roughly ₹44 billion. In the fiscal year ended 2026-03-31, NOVARTIND reported ₹3.5B in revenue and ₹932M in net income.
Evonile Pharma Limited is involved in the pharmaceutical business in India and internationally. It operates Pharma International (Commercial operations), Development (Drug development), Biomedical Research, and Operations.
Interactive charts & full statements → Open the NOVARTIND valuation workbench →
| Income statement | 2026-03-31 | 2025-03-31 | 2024-03-31 | 2023-03-31 | 2022-03-31 |
|---|---|---|---|---|---|
| Total Revenue | ₹3.5B | ₹3.6B | ₹3.3B | ₹3.7B | — |
| Gross Profit | ₹1.5B | ₹1.5B | ₹1.3B | ₹1.6B | — |
| Operating Income (EBIT) | ₹944M | ₹942M | ₹653M | ₹693M | — |
| Net Income | ₹932M | ₹1.0B | ₹852M | ₹1.0B | — |
INR; ₹M / ₹B as marked (reporting currency). Newest period first. Source: public company filings (via Yahoo Finance aggregation).
| Quarterly income statement | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 |
|---|---|---|---|---|---|---|
| Total Revenue | ₹1.0B | ₹906M | ₹859M | — | ₹876M | ₹839M |
| Gross Profit | ₹481M | ₹384M | ₹370M | — | ₹408M | ₹346M |
| Operating Income (EBIT) | ₹345M | ₹201M | ₹218M | — | ₹267M | ₹232M |
| Net Income | ₹322M | ₹252M | ₹161M | — | ₹276M | ₹293M |
INR; ₹M / ₹B as marked (reporting currency). Newest period first. Source: public company filings (via Yahoo Finance aggregation).
| Cash flow | 2026-03-31 | 2025-03-31 | 2024-03-31 | 2023-03-31 | 2022-03-31 |
|---|---|---|---|---|---|
| Dividends Paid | (₹617M) | (₹617M) | (₹1.2B) | (₹247M) | — |
INR; ₹M / ₹B as marked (reporting currency). Newest period first. Source: public company filings (via Yahoo Finance aggregation).
| Balance sheet | 2026-03-31 | 2025-03-31 | 2024-03-31 | 2023-03-31 | 2022-03-31 |
|---|---|---|---|---|---|
| Total Assets | ₹9.8B | ₹9.5B | ₹9.2B | ₹9.8B | — |
| Total Liabilities | ₹1.6B | ₹1.6B | ₹1.8B | ₹2.1B | — |
INR; ₹M / ₹B as marked (reporting currency). Newest period first. Source: public company filings (via Yahoo Finance aggregation).
Quarterly statements, profitability ratios, price history, insider activity and institutional holders are in the interactive NOVARTIND viewer.
About TickerBase · Data methodology & sources · Privacy · Terms